



Corporate Overview

RESprotect GmbH is a Dresden based, privately held Biotech company specialising in the development of drugs for the prevention and treatment of chemotherapeutic drug resistance and radiation therapy resistance.

RP101 is the company's first product candidate, a small molecule drug given orally to cancer patients in combination with standard of care chemotherapy. In two clinical studies, patients with advanced pancreatic cancer were shown to achieve significantly improved survival when compared to those receiving standard chemotherapy alone.



The company is located close to the Clinics of the University of Dresden, the Bio-Innovation-Centre and the Max-Planck-Institute for Molecular Cell Biology and Genetics.